New Antibody-Drug conjugate targets Hard-to-Treat cancers

NCT ID NCT06465069

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 8 times

Summary

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and others. The goal is to find a safe dose and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4052031 (an antibody-drug conjugate targeting Nectin-4)
What this could lead to: If successful, this could lead to a new treatment option for several advanced cancers that are hard to treat.
What could go wrong: This is an early Phase 1 trial, so the drug may not be effective or could have serious side effects. It will take years to know if it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm cervical cancer esophageal cancer Esophageal Neoplasms head and neck squamous cell carcinoma malignant pancreatic neoplasm metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian cancer pancreatic neoplasm prostate cancer renal pelvis carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma ureter cancer urinary bladder carcinoma urinary bladder neoplasm Urinary Bladder Neoplasms urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR BLADDER CANCER CERVICAL CANCER ESOPHAGEAL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA METASTATIC SOLID TUMOR NON-SMALL CELL LUNG CANCER OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RECURRENT SOLID TUMOR RENAL PELVIS CANCER TRIPLE NEGATIVE BREAST CANCER URINARY BLADDER NEOPLASM

Contacts and locations

Locations

Aichi Cancer Center Hospital
RECRUITING

Nagoya, 464-8681, Japan
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Beijing Cancer hospital
RECRUITING

Beijing, 100142, China
Catalan Institute of Oncology Duran i Reynals Hospital
RECRUITING

Barcelona, 8908, Spain
City of Hope National Medical Center
RECRUITING

Duarte, California, 91010-0269, United States
Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032-3729, United States
Florida Cancer Specialists and Research Institute
COMPLETED

St. Petersburg, Florida, 33705, United States
Hospital Madrid Norte Sanchinarro
RECRUITING

Madrid, 28050, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Virgen Del Rocio
RECRUITING

Seville, 41013, Spain
IU Simon Cancer Center
NOT_YET_RECRUITING

Indianapolis, Indiana, 46202, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029-6574, United States
Institut Gustave Roussy (Igr)
RECRUITING

Villejuif, 94805, France
Linear Clinical Research
RECRUITING

Nedlands, 6009, Australia
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)
RECRUITING

New York, New York, 10016, United States
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)
NOT_YET_RECRUITING

New York, New York, 10016, United States
National Cancer Center Hospital
RECRUITING

Chūōku, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
Renji Hospital, Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, 200000, China
START Midwest Cancer and Hematology Centers of W Michigan
RECRUITING

Grand Rapids, Michigan, 49546, United States
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at HealthOne
RECRUITING

Denver, Colorado, 80218, United States
South Texas Accelerated Research Therapeutics (START)
RECRUITING

San Antonio, Texas, 78229, United States
St Bartholomew's Hospital
RECRUITING

London, EC1A 7BE, United Kingdom
St Vincent's Hospital
RECRUITING

Darlinghurst, 2010, Australia
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, 510060, China
Tennessee Oncology PLLC
NOT_YET_RECRUITING

Nashville, Tennessee, 37203, United States
The Cancer Institute Hospital of JFCR
RECRUITING

Kōtō City, 135-8550, Japan
The Christie NHS Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
UCLA Department of Medicine-Hematology/Oncology
RECRUITING

Los Angeles, California, 90024, United States
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States
University of California, San Diego (UCSD) - Moores Cancer Center
NOT_YET_RECRUITING

La Jolla, California, 92093, United States
University of Chicago Hospital
RECRUITING

Chicago, Illinois, 60637, United States
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030-4000, United States
University of Utah - Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
Washington University School of Medicine in St. Louis
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.